C WorldWide Group Holding A S decreased its position in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 1.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 383,148 shares of the biopharmaceutical company’s stock after selling 5,136 shares during the period. C WorldWide Group Holding A S owned approximately 0.23% of Horizon Pharma PLC worth $4,858,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Bank of Montreal Can increased its position in Horizon Pharma PLC by 16.3% during the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 1,378 shares during the last quarter. Sheaff Brock Investment Advisors LLC increased its position in Horizon Pharma PLC by 5.0% during the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 500 shares during the last quarter. Family Management Corp bought a new position in Horizon Pharma PLC during the second quarter valued at $131,000. Ballentine Partners LLC bought a new position in Horizon Pharma PLC during the second quarter valued at $139,000. Finally, Teacher Retirement System of Texas increased its position in Horizon Pharma PLC by 12.8% during the second quarter. Teacher Retirement System of Texas now owns 12,941 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 1,466 shares during the last quarter. Institutional investors and hedge funds own 82.56% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “C WorldWide Group Holding A S Has $4.86 Million Holdings in Horizon Pharma PLC (HZNP)” was first published by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/11/12/c-worldwide-group-holding-a-s-has-4-86-million-holdings-in-horizon-pharma-plc-hznp.html.

Horizon Pharma PLC (HZNP) traded up $0.32 during mid-day trading on Friday, hitting $13.57. 2,833,700 shares of the company’s stock traded hands, compared to its average volume of 2,422,780. The stock has a market capitalization of $2,223.93, a price-to-earnings ratio of 9.83, a price-to-earnings-growth ratio of 1.15 and a beta of 1.32. Horizon Pharma PLC has a 1-year low of $9.45 and a 1-year high of $21.98. The company has a current ratio of 1.64, a quick ratio of 1.46 and a debt-to-equity ratio of 1.89.

Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.04. The business had revenue of $271.60 million during the quarter, compared to analyst estimates of $259.74 million. Horizon Pharma PLC had a negative net margin of 45.28% and a positive return on equity of 20.22%. The company’s quarterly revenue was up 30.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.70 earnings per share. sell-side analysts expect that Horizon Pharma PLC will post 0.72 EPS for the current year.

A number of research analysts have recently commented on the stock. Piper Jaffray Companies set a $18.00 price target on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Sunday, September 10th. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price target on shares of Horizon Pharma PLC in a report on Sunday, October 22nd. ValuEngine upgraded shares of Horizon Pharma PLC from a “hold” rating to a “buy” rating in a report on Monday, October 16th. BidaskClub cut shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $17.00 price target on shares of Horizon Pharma PLC in a report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $18.42.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.